The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapy in the management of neovascular age-related macular degeneration (nAMD) has revolutionize the treatment landscape, providing significant visual gains in patients with nAMD [1]. This evidence concerns the gene VEGFA and wet macular degeneration.